MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism
Go back to MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism| (NASDAQ: MBX) | Delayed: 62.91 -0.98 (1.53%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $63.89 | 52 Week High | $ | |||
| Open | $64.00 | 52 Week Low | $ | |||
| Day High | $64.05 | P/E | N/A | |||
| Day Low | $61.40 | EPS | $ | |||
| Volume | 932,363 | |||||
